ID
33063
Description
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella CRF Seiten: 268-336; 870-938
Keywords
Versions (2)
- 11/23/18 11/23/18 -
- 11/26/18 11/26/18 -
Copyright Holder
GSK group of companies
Uploaded on
November 26, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Immunogenicity of Combined Measles Mumps Rubella Varicella Vaccine for healthy 2 y.o children - 104020
Visit 1: Solicited Adverse Events - General Symptoms (All Groups)
Description
General Symptoms
Description
General Symptom 1
Description
Symptom 2
Description
Symptom 3
Description
Symptom 4
Description
Febrile convulsions - suspected signs of meningitis
Data type
boolean
Description
If Yes, please complete the Febrile Convulsions - Suspected Signs of Meningitis form
Data type
text
Description
Please report serious adverse events to GSK by telephone within 24 hours